Latest Conference Articles

December 12th 2013, 3:13pm

ASH Annual Meeting and Exposition

Brentuximab vedotin has demonstrated antitumor activity in the setting of relapsed or refractory DLBCL across a broad range of CD30 expression, including low or undetectable CD30 expression.

December 12th 2013, 1:50pm

San Antonio Breast Cancer Symposium

Adding the tyrosine kinase inhibitor dasatinib to standard aromatase inhibitor therapy with letrozole doubled PFS compared with letrozole alone in women with HR-positive, HER2-negative metastatic breast cancer.

December 12th 2013, 11:36am

San Antonio Breast Cancer Symposium

Carlos L. Arteaga, MD,discusses the CALGB 40603 trial, a neoadjuvant triple-negative breast cancer trial.

December 12th 2013, 8:20am

San Antonio Breast Cancer Symposium

Women aged 65 and older with hormone receptor-positive, axillary node-negative breast cancer may be able to forego radiation therapy after breast conserving surgery if they are treated with hormonal therapy and considered to be at low risk for breast cancer recurrence.

December 12th 2013, 7:39am

San Antonio Breast Cancer Symposium

C. Kent Osborne, MD, professor of medicine and molecular and cell biology, Baylor College of Medicine, discusses the impact of the results of the PRIME 2 trial, which looked at radiotherapy after surgery in women over 65 years old with breast cancer.

December 12th 2013, 6:24am

San Antonio Breast Cancer Symposium

The benefit of screening mammography is more consistent across studies than has previously been thought, according to an analysis of key screening studies presented at the 2013 San Antonio Breast Cancer Symposium.

December 12th 2013, 6:11am

San Antonio Breast Cancer Symposium

New evidence suggests that HER2-positive breast cancer may not only be immunogenic, but also that trastuzumab may relieve suppression of antitumor immunity.

December 11th 2013, 5:34pm

ASH Annual Meeting and Exposition

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

December 11th 2013, 4:02pm

San Antonio Breast Cancer Symposium

Jennifer Litton, MD, associate professor, Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, discusses the results of the BETH trial.

December 11th 2013, 2:59pm

San Antonio Breast Cancer Symposium

Sherene Loi, MD, PhD, on the association between immune cells and a pathologic complete response in patients with breast cancer after being given chemotherapy and trastuzumab.

December 11th 2013, 9:14am

ASH Annual Meeting and Exposition

Several trials of ibrutinib, an oral BTK inhibitor, either alone or in combination with currently used therapies for patients with chronic lymphocytic leukemia were presented at the 55th Annual Meeting of the American Society of Hematology.

December 10th 2013, 5:51pm

ASH Annual Meeting and Exposition

Richard R. Furman, MD, from the New York Weill Cornell Medical Center, discusses the ability to avoid the administration of chemotherapy when using novel agents, such as idelalisib, to treat patients with chronic lymphocytic leukemia.

December 10th 2013, 2:56pm

ASH Annual Meeting and Exposition

Imetelstat, a telomerase inhibitor, has demonstrated significant activity in myelofibrosis, including complete responses.

December 10th 2013, 12:51pm

ASH Annual Meeting and Exposition

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

December 10th 2013, 12:11pm

ASH Annual Meeting and Exposition

Adding ofatumumab to chlorambucil in patients with previously untreated chronic lymphocytic leukemia who are considered inappropriate for fludarabine improves clinical outcomes and is tolerable irrespective of patient age or fitness.

December 10th 2013, 6:23am

ASH Annual Meeting and Exposition

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

December 9th 2013, 5:09pm

ASH Annual Meeting and Exposition

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

December 9th 2013, 3:12pm

ASH Annual Meeting and Exposition

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory Waldenström's macroglobulinemia, and the responses to ibrutinib were durable.

December 9th 2013, 3:12pm

ASH Annual Meeting and Exposition

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

December 9th 2013, 9:26am

ASH Annual Meeting and Exposition

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.